Stockreport

TRITON3 Phase 3 Trial of Rubraca® (rucaparib) Achieves Primary Endpoint in Men with Metastatic Castration-Resistant Prostate Cancer with BRCA or ATM Mutations

Clovis Oncology, Inc.  (CLVS) 
Last clovis oncology, inc. earnings: 2/24 04:05 pm Check Earnings Report
PDF TRITON3 study evaluating Rubraca monotherapy versus chemotherapy or second-line androgen deprivation therapy in patients with metastatic castration-resistant prostate ca [Read more]